Drugs / NeuroEPO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07178678 | Nov 2025 → Mar 2030 expected | Alzheimer disease | University of Saskatchewan | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04110678 Comparator | Nov 2015 → Feb 2016 | Parkinson disease | International Center for Neurological Restoration, Cuba | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeuroEPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04110678 ↗ |
| Modality | Protein / enzyme biologic | “NeuroEPO is a new nasal formulation of recombinant EPO with a low content of sialic acid and without hematopoietic effects.” PMID 33780423 ↗ Jan 2021 |
| Route | Intranasal | “both treated intranasally either with the drug (1 mL, at a concentration of 1 mg/mL of NeuroEPO) or placebo once a week for 5 weeks.” PMID 33780423 ↗ Jan 2021 |